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ABSTRACT 
Generation of cAMP through Gs-coupled G protein-coupled receptor (GPCR) [e.g. 2-
adrenoceptor (β2AR), adenosine A2B receptor (A2BR)] activation, induces arterial smooth 
muscle relaxation, counteracting the actions of vasoconstrictors. Gs-coupled GPCR signalling 
is regulated by G protein-coupled receptor kinases (GRK) and arrestin proteins, and 
dysregulation of Gs/GPCR signalling is thought play a role in the development of 
hypertension, which may be a consequence of enhanced GRK2 and/or arrestin expression. 
However, despite numerous studies indicating that β2AR and A2BR can be substrates for 
GRK/arrestin proteins, currently little is known regarding GRK/arrestin regulation of these 
endogenous receptors in arterial smooth muscle. Here, endogenous GRK isoenzymes and 
arrestin proteins were selectively depleted using RNA-interference in rat arterial smooth 
muscle cells (RASM) and the consequences of this for β2AR- and A2BR-mediated adenylyl 
cyclase (AC) signalling were determined by assessing cAMP accumulation. GRK2 or GRK5 
depletion enhanced and prolonged β2AR/AC signalling, while combined deletion of GRK2/5 
has an additive effect. Conversely, activation of AC by A2BR was regulated by GRK5, but not 
GRK2. β2AR desensitization was attenuated following combined GRK2/GRK5 knockdown, 
but not by depletion of individual GRKs, arrestins, or by inhibiting PKA. Arrestin3 (but not 
arrestin2) depletion enhanced A2BR-AC signalling and attenuated A2BR desensitization, while 
β2AR-AC signalling was regulated by both arrestin isoforms. This study provides a first 
demonstration of how different complements of GRK and arrestin proteins contribute to the 
regulation of signalling and desensitization of these important receptors mediating vasodilator 
responses in arterial smooth muscle. 
 
Key words: Vascular smooth muscle, GRK, arrestin, adenosine A2B receptor, β2-adrenoceptor  
Abbreviations: AC, adenylyl cyclase; A2BR, adenosine A2B receptor; βAR, β-adrenoceptor; 
GPCR, G protein-coupled receptor; GRK, G protein-coupled receptor kinase; RASM, rat 
aortic smooth muscle cells; siRNA, small interfering RNA; VSMC, vascular smooth muscle 
cells 
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1. Introduction 
Maintaining a balance between the actions of vasoconstrictor and vasodilator inputs is 
vital for the control of vascular tone and blood vessel diameter [1]. Disturbances in this 
balance can lead to hypertension, which is an important risk factor in the development of 
major cerebral, cardiovascular and renal diseases [2]. Vascular tone is tightly regulated by an 
array of opposing vasoconstrictor and vasodilator molecules, many of which mediate their 
effects via specific G protein-coupled receptors (GPCRs) [2]. In general, vasoconstrictors 
(e.g. endothelin, angiotensin II, noradrenaline) bind to, and activate Gq/11/phospholipase C-
coupled GPCRs to increase intracellular Ca2+ concentrations and bring about their vaso-
regulatory actions. Conversely, vasodilators (e.g. noradrenaline, adenosine) interact with Gs-
coupled GPCRs, to activate adenylyl cyclase, producing cyclic-3’,5’-adenosine 
monophosphate (cAMP), which mediates smooth muscle relaxation through plasma 
membrane hyperpolarization and reduced myosin light chain phosphorylation [3, 4]. 
GPCR desensitization plays a critical role in limiting the duration and magnitude of 
GPCR activation, thus preventing prolonged or potentially damaging signalling. 
Desensitization is primarily mediated through the actions of a family of serine/threonine 
protein kinases, the G protein-coupled receptor kinases (GRKs). GPCR phosphorylation by 
GRKs enhances receptor affinity for arrestins 2 and/or 3, which can sterically suppress further 
interactions between receptor and G proteins [5, 6]. While vascular smooth muscle has been 
shown to express at least four of the seven members of the GRK family, accumulating 
evidence suggests that GRK2 may play a dominant role in regulating a number of 
vasoconstrictor GPCRs, including the 1D-adrenoceptor [7], angiotensin II type 1 [8], ETA 
endothelin [9], and P2Y2 [10] receptors. Moreover, we have found that in arterial smooth 
muscle, despite both being substrates for GRK2, P2Y2 and ETA receptor phosphorylation 
leads to preferential recruitment of arrestin2 or arrestin3, respectively [9-11]. 
Previous studies, conducted in a number of cell backgrounds, have highlighted GRK2 
as a key regulator of β-adrenoceptor (βAR) and A2 adenosine receptor (A2R) function [12-16]. 
Limited evidence is presently available supporting a role for GRK2 as a key regulator of βAR 
or A2R activity in vascular smooth muscle cells (VSMC). For example, βAR-stimulated 
cAMP generation in mouse aortic smooth muscle cells has been shown to be suppressed when 
GRK2 is over-expressed [17], and increased when GRK2 is depleted using a shRNAi 
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approach [18]. At present, a potential role for arrestin proteins in the regulation of βAR or 
adenosine A2R signalling in arterial smooth muscle has not been investigated. Furthermore, 
the molecular mechanisms by which endogenous GRK and/or arrestin proteins regulate 
signalling by the endogenous βAR or A2R populations have not been delineated in the 
vasculature. Considering that in rodent models of hypertension, the disease phenotype is 
accompanied by an arterial smooth muscle-specific increase in GRK2 [19, 20] and arrestin2/3 
protein expression [20], it is important to determine whether these proteins regulate βAR- 
and/or A2R-mediated vasodilator signalling in arterial smooth muscle. Therefore, we have 
utilized RNAi approaches specifically to deplete GRK and/or arrestin isoforms to identify 
their respective roles in the regulation of βAR and A2R signalling in arterial smooth muscle. 
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2. Methods 
2.1 Isolation of aortic smooth muscle cells from Wistar rats 
Adult Wistar rats (>300 g) were culled by stunning and cervical dislocation. The care 
and Schedule 1 killing of animals conformed to the requirements of the United Kingdom 
Animals (Scientific Procedures) Act 1986 Amendment Regulations (SI 2012/3039). Smooth 
muscle cells were isolated from the aorta of animals by enzymatic dissociation as previously 
described [21]. Cells were separated by gentle trituration in Dulbecco’s modified Eagle’s 
medium (DMEM) + GlutaMAX supplemented with 10% fetal calf serum, 100 IU/mL 
penicillin, 100 μg/mL streptomycin, and 2.5 μg/mL amphotercin B. Cells were maintained in 
5% CO2 in humidified air at 37°C in flasks and used for experiments between passages 3-6. 
2.2 Measurement of cAMP generation 
Rat aortic smooth muscle (RASM) cells were plated in 24-well plates and grown until 
near confluency. Cells were washed twice in Krebs-Henseleit buffer (KHB) (mM: HEPES, 
10; NaHCO3, 1.3; D-glucose, 11.7; MgSO4, 1.2;
 KH2PO4, 1.2; KCl, 4.7; NaCl, 118; CaCl2, 
1.3; pH 7.4) and left in KHB to recover for 10 min. Cells were treated with the 
phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX; 300 µM) during this period. 
Cells were then stimulated with agonist as indicated for each experiment before the reaction 
was terminated by the addition of trichloroacetic acid (TCA; 0.5 M). Samples were then 
processed and cAMP concentrations determined as described previously [22]. Since IBMX 
has been reported to bind to and inhibit adenosine receptors [23], rolipram (10 µM) was used 
instead in experiments assessing NECA-stimulated cAMP signalling. 
2.3 Assessing receptor desensitization using cAMP-based assays 
RASM were plated as described in the previous sub-section. To assess βAR 
desensitization cells were washed with KHB without IBMX, before stimulation for 15 min 
with isoprenaline (1 µM) as a desensitizing stimulus, or vehicle. Next cells were washed 3 
times with KHB containing IBMX (300 µM) and re-stimulated with a range of concentrations 
of isoprenaline in the presence of IBMX to define a concentration-response relationship, 
before the reaction was terminated with TCA (0.5 M). A similar protocol was applied to 
assess A2BR desensitization, however cells were pre-treated with the non-selective adenosine 
agonist NECA (10 µM) as a desensitizing stimulus, or vehicle for 30 min. Cells were then 
washed 3 times with KHB containing rolipram (10 µM) and re-stimulated with NECA. 
Samples were then processed and cAMP concentrations determined as described previously 
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[22]. Receptor desensitization was determined as a percentage for the responses in 
isoprenaline pre-treated cells compared to vehicle-treated cells.  
2.4 Knockdown of endogenous GRK2, and arrestin proteins in RASM cells 
RASM (2 × 106) cells were transfected with 10 nM negative-control (non-targeting 
sequence) or GRK2 (5′-GCAGGUACCUCCAGAUCUCtt-3′), GRK5 (5’-
CAGUGGAAAUGGUUAGAAAtt-3’), GRK6 (5’-GACCAAGACUUCUACCAGAtt-3’); 
arrestin2 (5′-GCCACUGACUCGGCUACAAtt-3′) or arrestin3 (5′-
GCCUUCUGUGCCAAAUCUAtt-3′) small interfering (si)RNAs (Applied Biosystems, UK), 
as previously validated by our group [10, 11]. siRNAs were introduced using the Lonza 
nucleofection system (Lonza, Cologne, Germany) according to the manufacturer's 
instructions. Transfected cells were grown for 48 h to allow for efficient knockdown of the 
target protein expression before experiments were performed. Specific protein depletion was 
quantified using standard western blotting techniques, exactly as described previously [9, 10]. 
2.5 Data and statistical analysis  
Data presented are from a minimum of 3 different cell preparations each obtained 
from a different rat, and are expressed as means ± SEM. Parametric data were analysed using 
one-way or two-way ANOVA as indicated, with appropriate post-hoc testing, outlined in the 
corresponding figure legends (GraphPad Prism v7.2, San Diego, CA). Where data were 
normalized, non-parametric ANOVA analysis using Kruskal-Wallis was applied. In all cases 
post-hoc tests were only applied when initial ANOVA testing revealed a significant (p<0.05) 
result.  
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3. Results 
3.1 Characterization of βAR and adenosine receptor signalling in RASM cells 
The non-selective β-adrenoceptor agonist, isoprenaline caused a concentration-
dependent increase in cAMP accumulation in isolated primary RASM cells, with a maximal 
effect observed at ≥300 nM and an EC50 value of 79 nM (Fig. 1A). Since previous reports 
suggested that vascular smooth muscle cells express a mixed population of β-adrenoceptor 
subtypes [24] and our preliminary studies indicated the presence of β1AR and β2AR mRNA, 
but the absence of β3AR transcripts (data not shown), we assessed the contributions made by 
β1AR and β2AR to isoprenaline-induced cAMP accumulation. Pre-incubation with a range of 
concentrations of the β2AR-selective antagonist ICI118,551 resulted in a biphasic inhibition 
of isoprenaline-induced cAMP accumulation, with two-site curve-fitting revealing pKB values 
of 9.23 ± 0.17 and 6.61 ± 0.14 (Fig. 1B), corresponding closely to published β2AR (pKB = 
9.26) and β1AR (pKB = 6.52) affinity estimates, respectively [25]. However, inclusion of the 
β1AR-selective antagonist CGP20712A (300 nM, 30 min pre-treatment), had no significant 
effect on isoprenaline-stimulated cAMP accumulation (Fig. 1C). Together, these data indicate 
that isoprenaline-stimulated cAMP accumulation in RASM is primarily mediated by β2AR 
(>80%), with a minor β1AR contribution. 
Adenosine mediates vaso-relaxatory responses in a variety of vascular beds [26], and 
RASM cells are reported to express a number of adenosine receptor subtypes [27]. Therefore, 
we first characterized which receptor subtype(s) could generate cAMP. The non-selective 
adenosine receptor agonist 5'-N-ethylcarboxamidoadenosine (NECA) induced concentration-
dependent cAMP accumulation with EC50 value of 3 M (Fig. 1D), which is in agreement 
with previously published values for A2B adenosine receptor (A2BR) activation [28]. NECA-
stimulated cAMP accumulation was significantly attenuated by pre-incubation of RASM cells 
with the A2BR-selective antagonist, MRS1754 (10 M), while addition of the A2AR-selective 
agonist CGS21680 did not stimulate cAMP accumulation (Fig. 1D). NECA-induced cAMP 
accumulation was unaffected by pre-incubation of RASM with PTx (100 ng/mL; 18 h), 
suggesting that Gi /o-coupled adenosine A1 or A3 receptors are not involved (Fig. 1E). 
Collectively, these data suggest that cAMP generation in RASM is primarily mediated by the 
A2BR subtype. 
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3.2 GRKs selectively regulate β2AR and A2BR coupling to adenylyl cyclase  
Previous studies have indicated involvements of GRK2, GRK5 and/or GRK6 in the 
regulation of β2AR signalling [19, 29-31] and GRK2 in the regulation of A2BR signalling [16]. 
We have examined the potential of these GPCR regulatory proteins to regulate native β2AR 
signalling in the RASM cell background. Exposure of RASM to individual anti-GRK2, anti-
GRK5 or anti-GRK6 siRNAs (each at 10 nM) resulted in isoenzyme-selective ≥75% 
reductions in GRK2, GRK5 or GRK6, compared to cells transfected with negative-control 
siRNA (see Fig. 2A, B). Depletion of GRK5 (but not GRK2 or GRK6) significantly, though 
transiently enhanced NECA-stimulated cAMP accumulation, with the most marked effect 
being observed at 5 min (Fig. 2C). Similar experiments performed with isoprenaline showed 
significantly enhanced β2AR-stimulated cAMP accumulations following knockdown of 
GRK2 or GRK5 (but not GRK6) (Fig. 2D). Moreover, depletion of both GRK2 and GRK5 
increased and prolonged the enhancement in isoprenaline-stimulated cAMP accumulation in 
RASM cells (Fig. 2D).  
To determine further the specificity of GRK interactions with β2AR/A2BR-mediated 
cAMP signalling we examined the effects of GRK inhibition on β2AR and A2BR-activated 
cAMP generation. NECA (10 M) produced a time-dependent increase in cAMP 
accumulation that was not significantly altered by pre-incubation with the GRK2/3 inhibitor, 
compound 101 (30 M, for 20 min; Fig. 2E); this was in contrast to the response stimulated 
by isoprenaline, where compound 101 caused a significant enhancement of cAMP 
accumulation throughout the time-course (Fig. 2E). In addition, depletion of GRKs 2, 5 or 6 
had no effect upon forskolin-stimulated cAMP production (Fig. 2F), suggesting that the 
enhanced agonist-mediated cAMP accumulation following GRK2 or GRK5 depletion was 
stimulus-specific. These data indicate a degree of GRK/receptor-specific selectivity, with 
GRK2/GRK5 required for modulation of β2AR/AC signalling, while A2BR/AC activity is only 
regulated by GRK5. 
3.3 Arrestin dependency of A2BR- and β2AR-stimulated cAMP accumulation in RASM 
As arrestins are reported to regulate signalling downstream of both A2BR and β2AR 
[30, 32], we therefore used isoform-specific anti-arrestin siRNAs to deplete arrestin 
expression, either alone or in combination, to investigate their roles in A2BR- and β2AR-
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stimulated cAMP accumulation in RASM cells. In agreement with our previous studies [11, 
20], application of anti-arrestin2/3 siRNAs induced isoform-selective ≥75% reductions of 
each arrestin isoform (Fig. 3A, B). In the presence of PDE inhibition, depletion of either 
arrestin2 or arrestin3 resulted in a marked increase in isoprenaline- and NECA-stimulated 
cAMP accumulation, respectively (Fig. 3C, E). In the absence of pharmacological PDE 
inhibition, enhancement of the isoprenaline-stimulated cAMP accumulation was only 
observed in RASM cells where arrestin2 (and not arrestin3) had been depleted (Fig. 3D). In 
contrast, enhanced NECA-stimulated cAMP generation was only observed after arrestin3, but 
not arrestin2 knockdown (Fig. 3E). Moreover, although PDE inhibition enhanced and 
prolonged the temporal profile of NECA-stimulated cAMP accumulation (Fig. 3E), the 
selectivity of A2BR/arrestin3 interaction was maintained in the presence or absence of PDE 
inhibition (Fig. 3E, F). 
3.4 Differential effects of PDE isoenzyme-selective inhibitors on isoprenaline-stimulated 
adenylyl cyclase activity in RASM cells 
Arrestins can act as scaffold proteins, promoting the recruitment of specific 
phosphodiesterase (PDE) isoenzymes to active βARs, a process that contributes to the 
regulation and compartmentalization of cAMP [33]. Therefore, the possibility that arrestins 
enhance β2AR-stimulated cAMP signalling by mediating the recruitment of specific PDE 
isoenzymes was investigated. Isoprenaline-stimulated cAMP accumulation was determined in 
the absence or presence of isoenzyme-selective PDE inhibitors, in RASM cells after arrestin2 
or arrestin3 knockdown. In agreement with data already reported (Fig. 3D), in the absence of 
PDE inhibition an enhanced isoprenaline-stimulated cAMP production was only observed in 
arrestin2-depleted cells (Fig. 4). However, in the presence of a broad spectrum PDE inhibitor 
(IBMX), cAMP accumulations were greater in both arrestin2- and arrestin3-depleted cells 
(Fig. 4). Inclusion of the PDE3-selective inhibitor siguazodan had little effect on the observed 
cAMP responses, however, inclusion of the PDE4-selective inhibitor rolipram caused cAMP 
accumulations similar to those observed in the presence of IBMX (Fig. 4).  
3.5 β2AR desensitization is regulated by a combination of GRK2 and GRK5 
β2AR desensitization was initially investigated in primary RASM cells utilizing a 
protocol involving pre-treatment of cells with a maximal concentration (1 M, 15 min) of the 
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non-selective βAR agonist isoprenaline; cells were then washed and re-challenged with a 
range of concentrations of isoprenaline. This pre-treatment protocol led to a 47 ± 5% (mean ± 
SEM; for n=5) attenuation of the cAMP response (to 1 µM isoprenaline re-challenge), with no 
apparent change in agonist potency (Fig. 5A). To assess whether the observed receptor 
desensitization was attributable to β1AR and/or β2AR subtypes, RASM cells were pre-treated 
with the β1AR-selective antagonist CGP20712A (300 nM, 30 min), prior to application of the 
desensitization protocol. Inclusion of CGP20712A had no significant effect on isoprenaline-
stimulated cAMP accumulation in agonist-naïve cells (Fig. 5B), or on the extent of receptor 
desensitization (Fig. 5C). These data strongly suggest that this protocol allows us to assess 
predominantly β2AR desensitization in a native arterial cell background. Comparison of the 
concentration-response curves indicated that agonist-pre-treatment only attenuated 
isoprenaline-stimulated cAMP accumulation at concentrations above 100 nM, and maximal 
cAMP accumulation was achieved with addition of 1 M (Fig. 5A). Thus for all future 
desensitization experiments we simplified our protocol, applying an isoprenaline (1 M; 15 
min) pre-treatment, followed by washing and a further application of a single concentration of 
isoprenaline (1 M) for 10 min in the presence of IBMX.  
As previous reports implicate GRK2, GRK5 and/or GRK6 in the regulation of β2AR 
signalling [19, 29-31], our initial studies examined the effects of depleting endogenous GRKs 
on the desensitization of β2AR in RASM. Isoprenaline-stimulation of cells transfected with 
negative-control siRNA yielded a similar profile of cAMP accumulation to that observed in 
untransfected RASM cells (cf. Fig. 5A, D). Equivalent degrees of β2AR desensitization were 
also observed in negative-control siRNA-transfected and untransfected RASM cells (cf. Fig. 
5A, D). In agonist-naïve cells, isoprenaline-stimulated cAMP accumulation was enhanced 
after GRK2 or GRK5 depletion, whereas depletion of GRK6 was without effect (Fig. 5E). 
Following agonist pre-treatment, the level of cAMP was significantly greater in RASM with 
depleted GRK5, compared to NC, anti-GRK2 and anti-GRK6 siRNA-treated cells (Fig. 5E). 
However, despite these changes the extent of receptor desensitization following pre-treatment 
with isoprenaline (1 M, 15 min) was similar in all siRNA-treated cells, suggesting that 
depletion of individual GRKs (2, 5 or 6) failed to prevent β2AR desensitization in RASM cells 
(Fig. 5F). In contrast, depletion of both GRK2 and GRK5 resulted in a significant reduction in 
β2AR desensitization in RASM cells (Fig. 5F).  
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Since PKA is also reported to play a role in β2AR desensitization [29], we pre-
incubated RASM cells with the cell-permeant PKA inhibitor, myristoylated 14-22 amide 
(PKAI, 5 M), before applying the standard desensitization protocol. Inclusion of the PKA 
inhibitor had no effect on extent of receptor desensitization following isoprenaline pre-
treatment (1 M, 15 min; Fig. 5D, E). Furthermore, addition of the cell-permeant PKAI did 
not alter the β2AR desensitization observed in GRK2/GRK5-depleted RASM cells (Fig. 5E, 
F). These data indicate that combined GRK2/GRK5 depletion is required to observe a 
significant attenuation in isoprenaline-induced β2AR desensitization (from a 45 ± 2% to 29 ± 
2% decline in maximal responsiveness; Fig. 5F), and that pharmacological inhibition of PKA 
has no detectable effect per se, or in combination with GRK2/GRK5 depletion.  
To complement our siRNA GRK knockdown approach, we also studied β2AR 
desensitization in the absence and presence of the GRK2/3 inhibitor, compound 101 [34, 35]. 
Addition of compound 101 (30 M) produced similar results to those obtained using the anti-
GRK2 siRNA approach, enhancing isoprenaline-mediated cAMP accumulation in both 
agonist-naïve and isoprenaline-pre-treated RASM cells (Fig. 5G). However, compound 101 
(30 M) had no effect on the extent of isoprenaline-induced β2AR desensitization (1 M, 15 
min; Fig. 5H).  
3.6 A2BR desensitization is regulated by GRK5 
As no previous studies have examined A2BR desensitization in RASM, or indeed the 
roles that GRKs play in this process, we investigated A2BR desensitization in control or GRK-
depleted cells. Initially, we utilized a pre-treatment protocol where cells were pre-incubated 
with vehicle-control or a high concentration of NECA (10 M), for various time-periods. 
Next cells were extensively washed and re-challenged with NECA (10 M), for 10 min in the 
presence of rolipram, before cAMP concentrations were measured and compared to those 
obtained in agonist-naïve cells. These data indicated a time-dependent desensitization of 
A2BR-stimulated AC activity, with maximal effects after 30 min pre-incubation with NECA 
(Fig. 6A). Thus, in all subsequent experiments A2BR desensitization was induced by a 30 min 
NECA (10 M) pre-treatment. When NC siRNA transfected RASM were subjected to the 
desensitization protocol, the degree of A2BR desensitization was similar to that obtained in 
non-transfected cells (44 ± 4% non-transfected vs 52 ± 2% NC siRNA-transfected cells). In 
agreement with our previous data, NECA-induced cAMP accumulation was enhanced in 
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agonist-naïve cells following knockdown of GRK5, but not after GRK2 or GRK6 depletion 
(Fig. 6B). Furthermore, depletion of GRK5 attenuated NECA-induced A2BR desensitization 
with respect to the AC readout (Fig. 6C), whereas knockdown of GRK2 or GRK6 had no 
effect.  
3.7 Comparison of the roles played by arrestin proteins in β2AR versus A2BR 
desensitization 
Utilizing the simplified protocol (see above) we examined the effects of isoprenaline 
or NECA pre-treatment on β2AR and A2BR desensitization of AC activity in the presence of 
PDE inhibition. As expected, knockdown of arrestin2 and/or arrestin3, alone or a 
combination, enhanced the ability of isoprenaline to stimulate cAMP accumulation in agonist-
naïve cells (Fig. 7A). Although the degree of β2AR desensitization following knockdown of 
arrestins was unaffected (Fig. 7B), the level of cAMP produced after agonist pre-treatment 
was significantly greater in RASM with depleted arrestin expression, than that observed in 
negative-control transfected RASM (Fig. 7A).   
In comparison, in agonist-naïve cells NECA-driven cAMP accumulation was 
enhanced after knockdown of arrestin3 when compared to NC siRNA-treated RASM (Fig. 
7C). Furthermore, combined suppression of arrestin2 and arrestin3 expression produced a 
similar effect to arrestin3 knockdown alone, and arrestin2 knockdown had no effect on on 
NECA-stimulated cAMP accumulation (Fig. 7C). Unlike for the β2AR, where suppression of 
arrestin2 and/or 3 expression failed to reverse desensitization of β2AR/AC coupling, 
knockdown of arrestin3 did produce a significant reversal of A2BR/AC desensitization (Fig. 
7D).  
3.8 Dynamin inhibition attenuates A2BR, but not β2AR desensitization 
 To examine whether receptor endocytosis plays a role in the desensitization of β2AR 
or A2BR, we pre-incubated RASM with the dynamin inhibitor Dyngo 4A (30 µM, 15 min) 
[37], before applying the standard desensitization protocols to examine each receptor subtype. 
Inclusion of Dyngo 4A alone caused a 50% reduction in the accumulation of cAMP produced 
by isoprenaline (1 µM) or NECA (10 µM) challenge in agonist-naïve cells over a 10 min 
period (Fig. 8A, B). Interestingly, following agonist pre-treatments, the presence of Dyngo 
4A significantly reduced the attenuation in cAMP response seen for NECA-challenged cells 
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(p<0.01; Fig 8B, C). In contrast, the desensitization observed as the cAMP readout following 
isoprenaline pre-challenge was not altered by the presence of the dynamin inhibitor (Fig. 8B, 
C).  
 
3.9 Temporal profile of β2AR and A2BR re-sensitization 
To examine time-courses of re-sensitization of β2AR- and A2BR-stimulated cAMP responses, 
RASM cells were subject to standard desensitization protocols (i.e. β2AR, isoprenaline (1 
µM) for 15 min; A2BR, NECA (10 µM) for 30 min) before extensive buffer washing over a 3 
min period beforer re-challenge. Cells were also allowed to re-sensitize for up to an additional 
60 min before agonist re-challenge. PDE inhibitors were included 5 min prior to the second 
agonist stimulation. Our data show that β2AR re-sensitization after pre-treatment with 
isoprenaline is rapid with near full recovery within 30 min (Fig 9). In contrast, A2BR re-
sensitization after pre-treatment with NECA is considerably slower (Fig. 9). 
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4. Discussion 
GPCR-mediated cAMP production plays a vital role in the regulation of arterial tone, 
inducing vessel relaxation [38], counteracting the effects of vasoconstrictors and preventing 
the switch to a contractile hypertensive phenotype. Indeed, dysregulation of Gs-coupled 
receptors such as the βARs and A2Rs has long been implicated in the development of 
hypertension [39-41]. The majority of GPCRs are negatively regulated by GRKs and arrestin 
proteins, and previous studies both in model cells and animal models have implicated various 
GRKs, arrestins and PKA in the regulation of βAR and A2R desensitization and downstream 
signalling pathways [16, 18, 29, 30, 42, 43]. Although three GRK isoforms [9], two arrestins 
[11] and PKA [21] expressed in RASM have the potential to regulate βAR/A2R signalling 
[16, 29, 30, 42, 44], a thorough understanding of which kinases and/or arrestins are required 
to mediate receptor signalling and/or desensitization in this tissue has yet to be fully 
determined. Therefore, we utilized previously characterized RNAi approaches and 
pharmacological inhibitors to address this unanswered question.  
VSMC are reported to express β1AR, β2AR and β3AR receptors [24], therefore we 
determined the relative contributions of each receptor to the production of cAMP in response 
to the non-selective βAR agonist isoprenaline. In agreement with previous findings [45], we 
observed that a mixed β1AR/β2AR population (with ≥4 times more β2AR than β1AR) 
contributed to the total isoprenaline-stimulated cAMP response. Furthermore, the β1AR-
selective antagonist CGP20712A did not alter the extent of isoprenaline-stimulated cAMP 
accumulation. Collectively, these data suggest that the β1AR population plays at most a minor 
role in isoprenaline-stimulated cAMP production, with the majority role played by the β2AR, 
implying that we examined β2AR (rather than β1AR) activity in this study. VSMC are also 
reported to express various adenosine receptors [27], therefore we characterised their 
contributions to cAMP accumulation in response to the non-selective adenosine agonist 
NECA. Our data show that NECA-induced cAMP production was unaffected by PTx pre-
treatment and the A2AR-selective agonist CGS21680 produced a weak response only at 
concentrations reported to interact with A2BR [16]. These findings, combined with the ability 
of the A2BR-selective antagonist MRS1754 to inhibit NECA-driven cAMP production, 
strongly suggests that NECA-mediated cAMP generation in RASM is mediated by A2BR 
activity. 
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Using agonist pre-treatment protocols [29, 42, 46], we report robust desensitization of 
β2AR- and A2BR-stimulated AC activity. Concurring with previous reports where removal of 
PKA phosphorylation sites within the β2AR failed to prevent receptor desensitization in 
HEK293 cells [29, 46], inhibition of PKA activity failed to affect acute cAMP production or 
desensitization of β2AR/AC activity. Contrastingly, GRK2 knockdown dramatically enhanced 
β2AR-induced AC activity, findings that are qualitatively similar to observations in murine 
VSMC [18] and human airway smooth muscle following GRK2 depletion [47]. In the heart 
GRK2-mediated β2AR phosphorylation is known to promote Gi coupling [48, 49], which may 
explain why cAMP levels are enhanced in RASM following GRK2 depletion. Nevertheless, 
the requirement for GRK2-mediated phosphorylation (presumably of the β2AR) appears 
central to mediating β2AR/AC desensitization, since the GRK2 inhibitor, compound 101, 
mimicked the effects of GRK2 knockdown. Conversely, despite previous work highlighting a 
role for GRK2 in the regulation of A2BR/AC activity in neuroblastoma cells [16], in RASM, 
NECA-driven cAMP accumulation was enhanced after GRK5 knockdown, yet unaffected by 
GRK2 inhibition or depletion. Collectively, these data demonstrate an exclusive and novel 
role for GRK5 in the regulation of A2BR/AC coupling and hint at cell background-dependent 
differences in selective GRK-GPCR interactions [50].  
Interestingly, GRK5 depletion also enhanced acute β2AR-stimulated cAMP 
accumulation, suggesting that both kinases are able to phosphorylate and desensitize 
β2AR/Gs/AC coupling. Moreover, depletion of both GRK2 and GRK5 was necessary to 
reduce desensitization, suggesting that either kinase can substitute for each other to induce 
β2AR desensitization. We were unable to completely reverse the robust desensitization of 
β2AR/AC coupling, even after depletion of both GRK2 and GRK5. However, our ~50% 
reversal of receptor desensitization is similar to previous observations with the β2AR [29, 42] 
A2BR [16] and other Gs-coupled receptors [50-52] and could simply reflect incomplete 
(typically 75-80%) depletion or inhibition of GRK isoforms. Although alternative kinases 
may contribute to β2AR or A2BR desensitization, we found no evidence to support a role for 
either GRK6 or PKA in β2AR desensitization, or GRK2 or GRK6 in A2BR desensitization. 
Furthermore, previous reports question the presence of GRK3 in arterial smooth muscle [7, 
9]. Moreover, since compound 101 inhibits both GRK2 and 3 [34] and no change in β2AR or 
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A2BR desensitization was observed in the presence of this compound, it seems that combined 
inhibition of GRK2/3 cannot prevent β2AR/AC or A2BR/AC uncoupling.   
Analysis of GRK/β2AR interactions in model cell systems may provide possible 
explanations for our findings. Despite having multiple potential GRK phosphorylation sites, 
the relative importance of each site to subsequent β2AR desensitization and/or recruitment of 
different signalling pathways is a subject of debate. While previous studies have identified 
S355/S356 residues as vital for GRK-mediated desensitization of human β2AR/AC activity 
[29], mass spectrometry analysis of the potential GRK phosphorylation sites suggested that 
GRK2 phosphorylates T360, S364, S396, S401, S407 and S411, whereas GRK6 
phosphorylates S355/S356 [42]. Although equivalent data are not available for the rat β2AR, 
with the exception of S407, human and rat β2ARs share the same putative phosphorylation 
sites, suggesting that the rat β2AR may show a similar GRK-mediated phosphorylation pattern 
to the human receptor. 
In HEK293 cells, both GRK2 and GRK6 were able to desensitize human β2AR/AC 
coupling, with some degree of cooperativity observed [42]. In contrast, we have shown that 
although individual knockdown of GRK2 or GRK5 enhanced acute cAMP production, β2AR 
desensitization was only attenuated following depletion of both kinases. These data imply that 
although there could be some overlap between GRK2 and GRK5 phosphorylation sites in the 
rat β2AR, unique sites may also be present. As evidence indicates that differential GRK 
phosphorylation patterns promote differential recruitment of arrestins, and in turn dictate the 
differential activation of downstream signalling pathways [42, 53], our findings highlight the 
possibility that GRK2 and GRK5 may differentially regulate β2AR signalling pathways in 
RASM. The rat A2BR contains 12 potential GRK phosphorylation sites (8 serine, 4 threonine), 
however, no studies have identified which are required for GRK-mediated desensitization. 
Nonetheless, deletion of the last 4 amino acids (329SLSL332) of the C-terminal tail, prevented 
desensitization of A2BR/AC signalling, implying that this region might be a key GRK-
phosphorylation site [32].   
Previous studies have identified arrestins as regulators of β2AR and A2BR signalling 
pathways in a variety of cellular backgrounds [30, 32, 33, 43, 54], but this has not been 
studied in RASM. Initial experiments suggested that both arrestin2 and arrestin3 are equally 
adept at regulating β2AR/AC signalling, since knockdown of either protein enhanced and 
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prolonged agonist-driven cAMP accumulation. Surprisingly, our desensitization studies 
indicate that arrestins do not play a role in the desensitization of β2AR/AC signalling, as even 
depletion of both arrestin isoforms failed to reverse receptor desensitization. It should be 
noted that although the percentage desensitization in all treatments was similar, the relative 
amount of cAMP produced was significantly greater in arrestin-depleted cells, even after 
desensitization. Therefore, it is conceivable that the effects of arrestins on β2AR/AC 
desensitization are masked due their ability to inhibit acu te β2AR/AC activity. In this regard 
both arrestins can act as agonist-adaptor scaffolds, to facilitate PDE4 recruitment to the β2AR 
[44, 55]. However, in contrast to previous studies [56] it would appear that in RASM it is 
arrestin2, rather than arrestin3, that performs this function. In RASM cells, in the absence of 
PDE inhibition, elevated cAMP production was only observed following arrestin2 
knockdown. Moreover, the isoprenaline-stimulated cAMP response was enhanced in the 
presence of PDE4, but not PDE3 inhibitors, suggesting a selective recruitment of PDE4. 
Interestingly, cAMP production was further enhanced following combined arrestin2 depletion 
and pharmacological inhibition of PDE4, suggesting that perhaps arrestin2 facilitates the 
targeting of PDE4 to the agonist-bound receptor. The interaction between arrestin2 and β2AR 
appears to be receptor-specific as arrestin2 plays no role in the regulation of A2BR/AC 
activity, which appears to be solely mediated by arrestin3. This raises the possibility that 
arrestin3 may play an equivalent role in recruiting PDE isoenzymes to the A2BR. However, 
unlike the β2AR a significant reversal of A2BR desensitization was observed in arrestin3 
depleted cells, which suggests that arrestin3 may also play a more traditional role in 
attenuating A2BR/Gs/AC coupling.   
It is noteworthy that receptor desensitization can differ depending upon whether the 
desensitization stimulus is chronic or acute, and that Gs-coupled receptors may be able to 
continue to signal at the cell-surface [36], and/or following internalization [37]. In the case of 
the 1AR, which shows continued signalling at the cell-surface, receptor activity is masked by 
the recruitment of PDE enzymes to the receptor microdomain. These findings chime with our 
data, where acute (over a 10 min time-course) signalling can be substantially enhanced 
following GRK or arrestin knockdown, possibly as a result of decreased receptor 
phosphorylation and arrestin/PDE recruitment. Interestingly, inhibition of dynamin-induced 
receptor internalization reduced the ability of either 2AR or A2BR to stimulate cAMP 
accumulation in agonist-naïve cells. At present it is unclear whether this is due to a non-
specific action, or alternatively, in agreement with previous data [37], both 2AR and A2BR 
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may continue to signal upon internalization. In addition, inhibition of dynamin reduced A2BR, 
but not 2AR desensitization in agonist pre-treated cells, indicating that A2BR desensitization 
is dependent on receptor internalization. 2AR [37] and A2BR [57] receptor internalization has 
been reported previously to be arrestin- and dynamin-dependent. Therefore, it is possible that 
endogenous RASM 2ARs are differently regulated, internalizing via a dynamin-independent 
mechanism, or perhaps more radically that endogenous RASM 2ARs are processed at the 
plasma membrane – a finding that might also account for the rapid 2AR re-sensitization that 
we have been observed. 
The development of hypertension results, at least in part, through an imbalance in the 
relative signalling inputs generated by contractile and relaxatory agents in VSM , which are 
mediated through activation of their cognate GPCRs. Here, we confirm that GRK2, GRK5 
and arrestin isoforms are negative regulators of β2AR/AC signalling, and highlight a similar 
novel role for GRK5 and arrestin3 in the regulation of A2BR signalling. Since the expression 
of GRK2 and arrestin proteins is known to increase in the early stages of hypertension [20], 
our findings suggest that, as has previously been postulated [18, 19], β2AR/AC activity would 
likely be suppressed during hypertension, leading to a reduced capacity to relax arteries. 
Logically, therapeutic strategies targeting GRK2 activity would seem beneficial and with 
recent developments in small molecule GRK inhibitors may eventually be possible. However, 
since GRK2 also negatively regulates the majority of contractile GPCRs [7, 9, 10, 18] it is 
debatable whether such therapies would be beneficial. In contrast, our findings suggest that 
targeting GRK5 to prolong A2BR mediated vessel relaxation might provide a more selective 
treatment for hypertension. 
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5. Conclusion 
In summary GRK2, GRK5 and arrestin2 negatively regulate β2AR-AC signalling in RASM, 
while GRK5/arrestin3 play similar roles in the regulation of A2BR signalling, implying that 
these mechanisms play a key role in arterial relaxation. Furthermore, arterial GRK2 and 
arrestin2/3 expression is enhanced in hypertension, which likely contributes to reduced 
arterial relaxation observed in this disorder. However, since GRK2 also negatively regulates a 
number of contractile GPCRs, our findings point to GRK5 providing a more promising target 
for the development of novel anti-hypertensives. 
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Figure Legends 
Fig. 1. Characterization of isoprenaline- or adenosine-induced cAMP generation in RASM.  
(A) RASM cells were stimulated with isoprenaline or forskolin at the indicated concentrations 
in the presence of IBMX (300 µM) for 10 min. (B) To determine the relative contributions 
that β1AR and β2AR play in determining total cAMP accumulation, RASM cells were pre-
incubated with increasing concentrations of the β2AR-selective antagonist ICI118,551 (for 30 
min) prior to the addition of isoprenaline (1 µM, 10 min), in the presence of IBMX (300 µM). 
(C) Isoprenaline concentration-response curves were generated in the presence or absence of 
the β1AR-selective antagonist CGP20712A (300 nM, 30 min pre-treatment). (D) RASM cells 
were pre-treated with either vehicle-control or the A2B receptor-selective antagonist MRS1754 
(10 M) for 30 min prior to the addition of increasing concentrations of the non-selective 
adenosine receptor agonist NECA, for a further 10 min, in the presence of the PDE4 inhibitor 
rolipram. Concentration-response curves were generated following addition of the selective 
A2A receptor agonist CGS21680. MRS1754 significantly inhibited ECA-stimulated cAMP 
accumulation *p<0.05, **p<0.01 (two-way ANOVA; Tukey’s post hoc test; when compared 
to vehicle control treated cells). E) RASM were pre-treated with PTx (100 ng/mL; 18 h) prior 
to stimulation with NECA (10 M), in the presence of rolipram. In all cases cAMP 
accumulation was determined as described previously (see Methods). Data are shown as 
means ± SEM for at least duplicate values each obtained in 6 (panels A, B) or 4 (panels C-E) 
RASM preparations from separate donor animals.   
 
Fig. 2. Suppression of GRK expression enhances β2AR- and A2B-stimulated adenylyl cyclase 
activity. Representative immunoblots (A) and cumulative data (B) show the extent of siRNA-
mediated GRK2, GRK5 or GRK6 depletion following transfection of RASM with specific 
anti-GRK siRNAs (10 nM, 48 h; data are means  SEM for at least duplicate values from 4 
separate animal preparations).  *p<0.01 (Kruskal-Wallis, Dunn’s post hoc test) indicates a 
significant reduction of targeted GRK expression vs control siRNA-treated cells. The effects 
of simultaneous transfection with GRK2 and GRK5 siRNAs (10 nM, 48 h; data are means  
SEM for at least duplicate values from 4 separate animal preparations).  *p<0.01 (Kruskal-
Wallis, Dunn’s post hoc test) indicates a significant reduction of targeted GRK expression vs 
control siRNA-treated cells are shown (C, D). The temporal-profiles of NECA (E) and 
isoprenaline (F) -stimulated cAMP accumulation in the absence of PDE inhibition are shown, 
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following siRNA-mediated depletion of GRK isoenzymes (see Methods). Data are means  
SEM for at least duplicate values from 6-8 separate animal preparations. GRK5 depletion 
enhanced NECA-stimulated adenylyl cyclase activity (E) *p<0.05; **p<0.01; vs control cells 
(two-way ANOVA; Tukey’s post hoc test). Knockdown of GRK2 or GRK5 enhanced 
isoprenaline-stimulated adenylyl cyclase activity (#p<0.05 vs control cells; two-way ANOVA; 
Tukey’s post hoc test), while combined knockdown of GRK2 and GRK5 further increased 
isoprenaline-stimulated cAMP accumulation (F) (*p<0.05; **p<0.01; vs other treatments, 
two-way ANOVA; Tukey’s post hoc test). Inclusion of the GRK2/3-selective inhibitor 
compound 101 (30 M, 20 min pre-treatment) enhanced and prolonged the temporal-profile 
of isoprenaline (1 µM), but not NECA (10 µM) stimulated cAMP accumulation (G) in the 
presence of PDE inhibitor (means  SEM for at least duplicate values from 6 separate animal 
preparations; **p<0.01; vs control cells, two-way ANOVA; Tukey’s post hoc test). H) 
Depletion of individual GRK expression has no effect on forskolin-stimulated AC activity. 
RASM cells were transfected with negative-control, anti-GRK2, anti-GRK5 or anti-GRK6 
siRNAs (10 nM) for 48 h prior to addition of the AC activator forskolin (10 M) for 10 min, 
in the presence of IBMX (300 µM). Data are means  SEM, n=6, from 6 separate animal 
preparations.  
Fig. 3. Time-course profiles of isoprenaline- or NECA-stimulated adenylyl cyclase activity in 
RASM following knockdown of arrestin2 and/or arrestin3. RASM were transfected with 10 
nM of negative-control (NC), anti-arrestin2 (AR2), anti-arrestin3 (AR3) or AR2/AR3 
siRNAs, for 48 h prior to the addition of agonists. (A) Representative immunoblots show 
arrestin2 (upper panel) or arrestin3 (lower panel) knockdown in RASM cells 48 h after 
transfection with AR2 or AR3 siRNAs. Cumulative data (separate experiments from 4 animal 
preparations) are shown in (B) (**p<0.01 vs NC siRNA-treated cells, Kruskal-Wallis, Dunn’s 
post hoc test). The prolife of isoprenaline-stimulated cAMP accumulation was determined in 
the presence (C) or absence (D) of the PDE inhibitor IBMX (300 M); and NECA-stimulated 
cAMP generation in the presence (E) or absence (F) of the PDE inhibitor rolipram (10 M). 
Data are expressed as means  SEM for at least duplicate values from 4 separate animals, 
*p<0.05; **p<0.01 two-way ANOVA, Sidak’s post hoc test compared to NC-treated RASM.  
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Fig. 4. Differential effects of PDE isoenzyme-selective inhibitors on isoprenaline-stimulated 
adenylyl cyclase activity in RASM. The effect of PDE3-selective inhibitor siguazodan (1 M) 
or PDE4-selective inhibitor rolipram (10 M) on isoprenaline-stimulated cAMP accumulation 
was determined in AR2- or AR3-depleted cells. PDE inhibitors were added 15 min prior to 
isoprenaline challenge (1 M, 10 min). cAMP accumulation was determined as described 
previously (see Methods). Data are means  SEM for at least duplicate values from 5 separate 
animal preparations; **p<0.01, ***p<0.001 two-way ANOVA; Tukey’s post hoc test 
compared to negative-control siRNA-treated cells. 
 
Fig. 5. Desensitization of β2AR-induced adenylyl cyclase activity in RASM is mediated by 
GRK2 and GRK5. A) β2AR-stimulated cAMP generation in non-transfected RASM, is shown 
in the presence or absence of isoprenaline pre-treatment (1 µM, 15 min, see Methods). Data 
are means ± SEM for n=5 separate preparations from 5 animals; p<0.01 (two-way, ANOVA, 
Tukey’s post hoc test), indicates a significant reduction in isoprenaline-driven cAMP 
generation following agonist pre-treatment. B) To delineate the relative contributions played 
by β1AR and β2AR receptors in the overall isoprenaline induced desensitization of adenylyl 
cyclase activity, RASM were pre-incubated with the β1AR selective antagonist CGP20712 
(300 nM, 30 min) prior to application of our standard receptor desensitization protocol. Data 
are means ± SEM for n=4 separate preparations from 4 animals, and show a significant 
reduction (p<0.01 two-way ANOVA, Tukey’s post hoc test) in isoprenaline-driven cAMP 
production when compared to their relative non-pre-treated controls (** +CGP samples / # -
CGP samples). (C) Cumulative data showing that the degree of receptor desensitization was 
similar in the presence and absence of CGP20712 (data are means ± SEM for n=5 separate 
preparations from 5 animals). The effects of GRK2 depletion or PKA inhibition on acute 
isoprenaline-stimulated cAMP production is shown in (D). Data are expressed as means  
SEM for n=6-10 from up to 10 separate animal preparations (**p<0.01, two-way ANOVA; 
Sidak’s post hoc test, when compared to negative-control (NC) siRNA- or PKAI-treated 
cells). The extent of isoprenaline (1 µM, 15 min)-induced β2AR (E, F) of cAMP generation 
are shown, following the depletion of GRK2, 5 or 6 (data are means  SEM for n=6-8, from 
6-8 separate animal preparations). Depletion of GRK2 or GRK5 enhanced cAMP generation 
in non-pre-treated RASM (**p<0.01 vs NC; two-way ANOVA; Tukey’s post hoc test), while 
GRK5 and combined GRK2/5 knockdown increased isoprenaline-stimulated cAMP 
accumulation in agonist pre-treated RASM (#p<0.01 vs NC; two-way ANOVA; Tukey’s post 
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hoc test). The extent of β2AR desensitization of isoprenaline-stimulated cAMP generation is 
shown (G) when RASM cells were pre-incubated with vehicle-control or the GRK2/3-
selective inhibitor compound 101 (30 M) for 20 min prior to application of the standard 
desensitization protocol. Data are means  SEM for n=4, from 4 separate animal preparations. 
Inclusion of compound 101 enhanced (**p<0.01; #p<0.05 vs control cells, two-way ANOVA; 
Tukey’s post hoc test) isoprenaline-stimulated cAMP accumulation in both naïve (**) and 
isoprenaline pre-treated (#) cells. Cumulative data (H) show the degree of β2AR 
desensitization, measured as the percent change in cAMP generated by 1 M isoprenaline in 
agonist-pre-treated (R2) compared to non-pre-treated (R1) RASM.  
 
Fig. 6. Desensitization of A2BR-stimulated adenylyl cyclase activity in RASM is mediated by 
GRK5. A) RASM were stimulated with NECA (10 µM) for varying time periods prior to 
washing and reapplication of NECA (10 µM) for a further 10 min in the presence of rolipram 
(10 µM). Data (means  SEM n=6, from 6 separate animal preparations) show the time-
dependent desensitization (**p<0.01 vs vehicle pre-treated cells; one-way ANOVA; Tukey’s 
post hoc test) of A2BR-stimulated AC activity. The extent of NECA (10 µM, 30 min)-induced 
A2BR desensitization (B) of cAMP generation are shown, following the depletion of GRK2, 5 
or 6 (data are means  SEM for n=6-8, from 6-8 separate animal preparations). Depletion of 
GRK5 enhanced NECA-stimulated cAMP generation in non-pre-treated RASM (**p<0.01 vs 
NC; two-way ANOVA; Tukey’s post hoc test).  Cumulative data show the degree of A2BR 
(C) desensitization, measured as the percent change in cAMP generated by 10 M NECA, in 
agonist-pre-treated (R2) compared to non-pre-treated (R1) RASM cells (means  SEM, n=6-8 
from 6-8 separate animal preparations). GRK5 knockdown attenuated A2BR desensitization 
(C) (*p<0.05 vs NC-treated cells; Kruskal-Wallis, Dunn’s post hoc test).    
 
Fig. 7. Differential effects of arrestin depletion on the desensitization of β2AR- and A2BR-
stimulated adenylyl cyclase signalling. To determine whether arrestins regulate isoprenaline-
induced β2AR (A, B) or NECA-induced A2AR (C, D) desensitization, RASM were transfected 
with 10 nM of negative-control (NC), anti-arrestin2 (AR2), anti-arrestin3 (AR3) or anti-
arrestin2 and anti-arrestin3 siRNAs, for 48 h before application of the standard desensitization 
assays (see Methods). Cumulative data show the degree of β2AR (B) or A2BR (D) 
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desensitization. Data are expressed as means  SEM (n=7-10 separate experiments from 7-10 
separate animals preparations) for the percent change in cAMP generated by 1 M 
isoprenaline for of β2AR and 10 µM NECA for A2BR in agonist-pre-treated (R2) compared to 
naïve (R1) RASM cells.  
 
Fig 8.  The dynamin inhibitor Dyngo 4A attenuates A2BR but not 2AR desensitization. 
RASM cells were pre-treated with vehicle control or Dingo 4A (30 µM) for 15 min prior to 
being subjected to the standard desensitization protocols (A) isoprenaline 1 µM, 15 min or (B) 
NECA 10 µM, 30 min pre-treatments. Cells were then washed and stimulated for 10 min with 
either (A) isoprenaline (1 µM) or (B) NECA (10 µM) in the presence of IMBX (300 µM) or 
rolipram (10 µM), respectively. The data (means  SEM; n=3 separate experiments from 3 
separate animals preparations) show that agonist pre-treatment caused significant decreases in 
cAMP accumulation (**p<0.01 vs non-pre-treated cells; two-way ANOVA; Tukey’s post hoc 
test). Dyngo 4A treatment inhibited acute isoprenaline and NECA-stimulated cAMP 
accumulation (#p<0.01 vs vehicle control; two-way ANOV ; Tukey’s post hoc test). 
Cumulative data (C) show the degree of β2AR and A2BR desensitization, measured as the 
percent change in cAMP generated by 1 M isoprenaline or 10 µM NECA in agonist-pre-
treated (R2) compared to non-pre-treated (R1) RASM. Data are expressed as means  SEM 
(n=3 separate experiments from 3 separate animals preparations). Dyngo 4A also attenuated 
A2BR but not 2AR desensitization (**p<0.01 vs vehicle control; two-way ANOVA; Tukey’s 
post hoc test). 
 
Fig 9. Time-course of β2AR and A2BR re-sensitization. RASM cells were subjected to the 
standard desensitization protocols (β2AR- 15 min isoprenaline 1 µM; A2BR- 30 min NECA 10 
µM), before washing 3 times with KREB buffer. Cells were then allowed to recover for up to 
45 min before a second agonist challenge (1 µM isoprenaline, or 10 µM NECA) for a further 
10 min in the presence of phosphodiesterase inhibitors. Cumulative data show the degree of 
β2AR or A2BR desensitization. Data are expressed as means  SEM (n=3 separate experiments 
from 3 separate animals preparations) for the percent change in cAMP generated by 1 M 
isoprenaline for of β2AR and 10 µM NECA for A2BR in agonist-pre-treated (R2) compared to 
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naïve (R1) RASM cells (*p<0.05, **p<0.01 vs agonist naïve cells; Kruskal-Wallis, Dunn’s 
post hoc test).  
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Highlights  
 Depletion of GRK2 or GRK5 enhanced and prolonged 2AR adenylyl cyclase activity 
 Combined GRK2/GRK5 knockdown further enhanced 2AR adenylyl cyclase activity 
 Combined knockdown of GRK2 and GRK5 attenuated 2AR receptor desensitization  
 Depletion of GRK5 enhanced acute adenosine A2B-stimulated adenylyl cyclase 
activity  
 Adenosine A2B receptor desensitization was GRK5 and arrestin3 dependent   
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